Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11608376 Tumor-targeted agonistic CD28 antigen binding molecules

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Tanja Fauti0

Thomas Hofer0

Christian Klein0

Ekkehard Moessner0

Guy Georges0

Jean-Baptiste Vallier0

Jenny Thom0

Johannes Sam0

...

Date of Patent

March 21, 2023

0

Patent Application Number

167212720

Date Filed

December 19, 2019

0

Patent Citations

US Patent 10253110 Anti-FAP antibodies and methods of use

0

US Patent 10184009 Mutant interleukin-2 polypeptides

0

US Patent 10464981 Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules

0

US Patent 10323098 Mutant interleukin-2 polypeptides

0

US Patent 10392445 Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

0

US Patent 10316104 Immunoconjugates

0

US Patent 10202464 Immunoconjugates

0

US Patent 10577429 Anti-FAP antibodies and methods of use

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

0

0

...

The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11608376 Tumor-targeted agonistic CD28 antigen binding molecules

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool